Market Access News | pharmaphorum

News

In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

League tables for NHS trusts will end the postcode lottery of care, says the government, but not all are convinced.

News

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.

News

The Bay State is the first to require insurers to cover the shot for everyone, despite conflicting guidance from RFK's HHS on who should get the jab.

News

The FDA's earlier decision to publish complete response letters was largely a repackaging of existing information, but now it has gone much further.